US - ES
Go to
Estados Unidos (español)
site
Over 8 million parents across the world have already trusted MiYOSMART.¹ Will you?
They aim to:
This information can help you assess if a treatment is the right solution for your child with an Eye Care Professional.
We’ve conducted multiple clinical studies in different age groups and parts of the world,2-4 so we are confident that MiYOSMART spectacle lenses are suitable for most children of different ages and backgrounds.
The D.I.M.S. Technology used in MiYOSMART spectacle lenses is based on a well-established and widely accepted scientific theory.5,6
• MiYOSMART spectacle lenses are generally well tolerated among children3, 9
• They are a non-invasive solution, unlike other treatments out there (like atropine or Ortho-K), and it usually only takes children a few days to adapt to their new MiYOSMART spectacle lenses
• Your child may occasionally notice blurred vision through the defocus zone of the lenses, but the central zone remains clear2, 3, 8, 9
• Some children experience ghost image, dizziness and headache, but these side effects are rare and short-lived2, 8
• A 6-year clinical study in Hong Kong showed no long-term side effects from wearing MiYOSMART spectacle lenses7
MiYOSMART spectacle lenses don’t cause glare sensitivity or worsen contrast vision. Thus, they don’t impair vision in traffic, neither alone nor with low-dose atropine eye drops.10 This means that after a 2-week adaptation period, your child can go cycling with no distracting glare from traffic lights or other vision disturbances.
MiYOSMART spectacle lenses work in synergy with low-dose atropine eye drops. In fact, recent clinical studies from Europe4 and China11 found that the combination treatment of MiYOSMART spectacle lenses and low-dose atropine eye drops was more effective, than MiYOSMART or atropine alone. However, this is a treatment decision that should be made under the supervision of an Eye Care Professional.
If your child stops their treatment with MiYOSMART spectacle lenses, myopia will not ‘bounce back’ to what it was before treatment.7 This is unlike other popular treatment methods, like high-dose atropine eye drops or orthokeratology.12, 13
MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.
MiYOSMART spectacle lenses may not be able to address individuals’ conditions due to natural deficiencies, illness, pre-existing medical conditions and/or advanced age of consumers. The information contained herein is for general information and is not intended to constitute medical advice. Please consult your Eye Care Professional for more information prior to the use of MiYOSMART spectacle lenses.
Based on number of MiYOSMART spectacle lenses sold per HOYA sales data on file as of June 2022.
Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-8. DOI: 10.1136/bjophthalmol-2018-313739.
McCullough S, Barr H, Fulton J, et al. 2-Year Multi-Site Observational Study of MiYOSMART myopia control spectacle lenses in UK children:1-year results (Abstract). Invest Ophthalmol Vis Sci. 2023;64(8):4945.
Nucci P, Lembo A, Schiavetti I, et al. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. PLoS One. 2023;18(2):e0281816. DOI: 10.1371/journal.pone.0281816.
Troilo D, Smith EL, 3rd, Nickla DL, et al. IMI - Report on Experimental Models of Emmetropization and Myopia. Invest Ophthalmol Vis Sci. 2019;60(3):M31-M88. DOI: 10.1167/iovs.18-25967.
Nemeth J, Tapaszto B, Aclimandos WA, et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol. 2021;31(3):853-83. DOI: 10.1177/1120672121998960.
Lam CSY, Tang WC, Zhang HY, et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023;13(1):5475. DOI: 10.1038/s41598-023-32700-7.
Lam CSY, Tang WC, Qi H, et al. Effect of Defocus Incorporated Multiple Segments Spectacle Lens Wear on Visual Function in Myopic Chinese Children. Transl Vis Sci Technol. 2020;9(9):11. DOI: 10.1167/tvst.9.9.11.
Lu Y, Lin Z, Wen L, et al. The Adaptation and Acceptance of Defocus Incorporated Multiple Segment Lens for Chinese Children. Am J Ophthalmol. 2020;211:207-16. DOI: 10.1016/j.ajo.2019.12.002.
Kaymak H, Mattern AI, Graff B, et al. Safety of DIMS Spectacle Lenses and Atropine as Combination Therapy for Myopia Progression. Klin Monbl Augenheilkd. 2022;239(10):1197-205. DOI: 10.1055/a-1930-7116.
Huang Z, Chen XF, He T, et al. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. Sci Rep. 2022;12(1):22311. DOI: 10.1038/s41598-022-25599-z.
Cho P, Cheung SW. Discontinuation of orthokeratology on eyeball elongation (DOEE). Cont Lens Anterior Eye. 2017;40(2):82-7. DOI: 10.1016/j.clae.2016.12.002.
Tong L, Huang XL, Koh AL, et al. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009;116(3):572-9. DOI: 10.1016/j.ophtha.2008.10.020.